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Summary
The components and reactions of the fibrinolysis system are
well understood. The pathway has fewer reactants and inter-
actions than coagulation, but the generation of a complete
quantitative model is complicated by the need to work at the
solid-liquid interface of fibrin. Diagnostic tools to detect dis-
ease states due to malfunctions in the fibrinolysis pathway
are also not so well developed as is the case with coagulation.
However, there are clearly a number of inherited or acquired
pathologies where hyperfibrinolysis is a serious, potentially
life-threatening problem and a number of antifibrinolytc
drugs are available to treat hyperfibrinolysis. These topics will
be covered in the following review.
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The biochemistry of fibrinolysis
The basic mechanisms and regulation of fibrinolysis have
been reviewed recently (Longstaff & Kolev, 2015) and will
not be covered in detail. In summary, fibrinolysis is readily
considered as two consecutive steps: (i) the generation of
plasmin by plasminogen activators, and (ii) the digestion of
fibrin by plasmin. The whole system is kept in check by a
system of protease inhibitors and other regulatory mecha-
nisms. Some key reactions and structural background are
highlighted in Fig 1.
It is important to remember that fibrin is not a passive
target in fibrinolysis but plays an important regulatory role
through the binding of reactants and focussing plasmin activ-
ity at cleavage sites (Varju et al, 2014). During the course of
fibrin degradation, plasmin proteolysis generates C-terminal
lysines, which provide new binding sites, primarily for
plasminogen and plasmin (Silva et al, 2012) and these nas-
cent binding sites constitute an important positive feedback
mechanism to accelerate fibrin degradation. Binding to lysine
residues in fibrin can be blocked by soluble fibrin analogues,
such as aminohexanoic acid (AHA, also known as epsilon
aminocaproic acid, EACA) or tranexamic acid (TXA), which
are discussed below. Tissue-type plasminogen activator
(tPA)-fibrin binding can occur through lysine interactions
with its kringle 2 domain, but the finger domain with differ-
ent specificity is dominant (Longstaff et al, 2011; Silva et al,
2012). Urokinase-type plasminogen activator (uPA) does not
bind to fibrin, and is more sensitive to the conformation of
plasminogen, which is affected by lysine residues in fibrin
and free lysine analogues in solution (Sinniger et al, 1999;
Silva et al, 2012). Recent crystal structures of plasminogen
have greatly extended our understanding of the intra-mole-
cular interactions behind these structural changes, providing
detailed molecular models to explain how plasminogen struc-
ture can regulate its activation (Xue et al, 2012; Law et al,
2013). Cell surface plasminogen activation shares some simi-
larities with fibrin-bound plasminogen activation, however
this topic is beyond the scope of the current review. The par-
ticular example of enhanced cell surface plasminogen activa-
tion in acute promyelocytic leukaemia is covered below.
Inhibitors of fibrinolysis
As in the case of coagulation, regulation of fibrinolysis
involves dedicated serpin protein inhibitors, operating at the
level of plasminogen activation and plasmin action, outlined
in Figs 1 and 2. A quite different mode of inhibition of fibri-
nolysis is accomplished by thrombin activatable fibrinolysis
inhibitor (TAFIa, also termed CPB2, CPU). TAFI (proCPU),
the zymogen form, is activated by thrombin or plasmin, but
primarily by thrombin/thrombomodulin to TAFIa, a zinc-
dependent carboxypeptidase that removes C-terminal lysine
(and arginine) residues from fibrin thereby reducing the
number of binding sites available for plasminogen and plas-
min. The clinical consequences of disturbances in levels of
a2 plasmin inhibitor (a2-PI), plasminogen activator inhibitor
type 1 (PAI-1, also termed SERPINE1) and TAFI are dis-
cussed below. The gross structure of fibrin clots, including
fibrin fibre thickness and branching, cellular components and
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other associated blood borne molecules, also modify clot
physical and biochemical properties and susceptibility to lysis
(Bridge et al, 2014). Hence the rate of fibrin clot breakdown
is partly determined at the clot formation stage and has a
bearing on the presentation of bleeding complications, as
described in the section on secondary hyperfibrinolysis
below.
Recent work on highly charged polymers including
polyphosphate from platelets, DNA and histones from neu-
trophils, and exogenous heparinoids, provide interesting new
insights into factors regulating clotting and lysis (Smith &
Morrissey, 2008; Longstaff et al, 2016). A diagrammatic rep-
resentation of components and interactions of the fibrinolysis
pathway relevant to this review is presented in Fig 2.
Diagnostic tools to measure disturbed
fibrinolysis
Detecting and measuring fibrinolysis is less standardized than
is the case with coagulation where batteries of tests are rou-
tinely performed using high throughput automated analysers
and standardized reagents to diagnose coagulation defects or
monitor anticoagulation therapy, for example. Ongoing
fibrinolysis can be detected by fluctuations in fibrinolytic
components, such as plasmin-a2-PI complexes, D-dimer for-
mation and depletion of circulating plasminogen and fibrino-
gen. Other fibrinolysis proteins, such as antigen levels of
PAI-1, tPA and TAFI, or activity of PAI-1 or TAFIa are also
used as markers of the state of the fibrinolysis system. Data
on individual haemostasis components do not give a com-
plete picture of the fibrinolytic system and global assays are
an alternative option. Global assays of haemostasis is a huge
topic and the subject of several recent reviews [e.g. (van Gef-
fen & van Heerde, 2012)]. Again, coagulation assays domi-
nate, from simple time courses of clotting of plasma or
whole blood to more sophisticated thrombin generation tests
where thrombin activity is monitored by following hydrolysis
of chromogenic or fluorogenic substrates after coagulation is
triggered in re-calcified plasma. There is no equivalent sys-
tem for directly measuring plasmin evolution during activa-
tion of the fibrinolytic system, but there are several
variations of clot lysis assays which rely on turbidity changes
as clots are formed and lysed (He et al, 2007; van Geffen &
van Heerde, 2012). Parameters derived from such time
courses are used to assess fibrinolytic capacity of test plasma,
but this is not achieved under normal circumstances, on a
Fig 1. Plasminogen generation and inhibition. Activation of the zymogen plasminogen to the serine protease plasmin is generally a simple pep-
tide bond cleavage (at Arg561) catalysed by tissue-type plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA). However,
the underlying mechanisms of these two plasminogen activators are inherently different, which is important when considering their regulation.
uPA is generated from a zymogen, single chain precursor, scuPA, whereas tPA is constitutively active in single chain and two chain forms (Thel-
well & Longstaff, 2007). tPA activity is poor in free solution but stimulation is achieved via a co-localization mechanism relying on the binding
of plasminogen and tPA in close proximity on the fibrin surface (Horrevoets et al, 1997). Plasminogen binding is accomplished through kringle
(K) domains, of which there are 5 with different affinities and specificities although K1, K4 and K5 seem to be most important for binding to
lysine residues in fibrin. The primary inhibitor of tPA and uPA is the serpin, plasminogen activator inhibitor 1 (PAI-1). PAI-1 reacts rapidly with
both target enzymes, although the rate is modulated by the presence of fibrinogen and fibrin (Thelwell & Longstaff, 2007). Similarly, a2-plasmin
inhibitor (a2-PI also known as a2-antiplasmin) reacts very rapidly with plasmin in free solution but the rate is significantly compromised in the
presence of fibrin and lysine analogues. AP, activation peptide; PAP, plasmin-antiplasmin complex; AS, active site; AHA, 6-aminohexanoic acid;
TXA, tranexamic acid.
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reasonable timescale, without the addition of a plasminogen
activator, usually tPA. Thus it is not possible to get informa-
tion on the intrinsic activity of tPA or subtle changes in the
balance with PAI-1. Another approach, which has been
around for many years, is the Euglobulin Clot Lysis Time
(ECLT). In this case, a plasma fraction is precipitated by acid
treatment then re-dissolved and this ‘euglobulin fraction’ is
assessed for fibrinolytic capacity. Although additional plas-
minogen activator is unnecessary, the euglobulin fraction
contains a different mix of proteins than plasma, including
60–70% of fibrinogen and plasminogen and 90% of tPA, but
is depleted of inhibitors PAI-1 and TAFI (at around 40%)
and, most significantly, <10% a2-PI (Smith et al, 2003)
(these values may vary with the precise methods used to pre-
cipitate the euglobulin fraction). The development of whole
blood assays is potentially very advantageous from the point
of view of including all plasma components and also cells,
most importantly platelets, which in addition to modifying
clot structure during clot retraction (Tutwiler et al, 2016),
are a source of PAI-1. The most obvious problem when
using whole blood is the handicap of not easily being able to
use optical methods. One way around this has been devel-
oped by Rijken et al (2012) who employed enzyme-linked
immunosorbent assay-based methods to detect fibrin degra-
dation products in clotted-lysing blood samples, while using
aprotinin-treated parallel samples as baseline (aprotinin is a
potent plasmin inhibitor) (Rijken et al, 2012). A different
approach to monitoring clot development, stabilization and
lysis relies on viscoelastic techniques, known as thromboelas-
tography (commercially available as TEG) or rotational
thromboelastometry (ROTEM). These methods commonly
employ re-calcified whole blood with or without additional
factors depending on the test or component(s) of interest
(Luddington, 2005). The basic technique is old but publica-
tions citing TEG or ROTEM in their abstracts have increased
around 20-fold since 2000 and they have been applied to
investigate haemostasis in research and clinical studies,
including monitoring coagulation factor replacement therapy
in haemophilia, or during surgery, and in trauma and sepsis.
Besides the advantages of using whole blood, these methods
can be used in a near-patient context and generate rapid
results to assist clinical decision-making. On the downside,
the methods are not well standardized and interpretation of
the many readouts available from the profiles generated by
TEG and ROTEM is not always simple. However, these are
methods able to identify hyperfibrinolysis.
Fig 2. Overview of fibrinolysis including signif-
icant reactions, markers and points where dis-
turbance may lead to clinical bleeding. Liver
synthesises and releases fibrinogen (Fg), plas-
minogen (Pg), a2-plasmin inhibitor (AP),
thrombin activatable fibrinolysis inhibitor
(TAFI) into the blood and takes up circulating
fibrinogen and fibrin degradation products
(FgDP, FDP, D-D), as well as the complexes of
proteases and their inhibitors (AP, plasmino-
gen activator inhibitor 1, PAI). Fibrin and cells
(myeloid precursor cells in acute promyelocytic
leukaemia, APL, or malignant cells in cancer)
provide a template for binding of plasminogen
activators (tissue-type, tPA and urokinase-type,
uPA) and plasminogen for more efficient gen-
eration of plasmin (Pn). Cell surface activation
complexes are assembled on annexin 2 (Ax2)
and S100A10 (p11) tetramers in APL or uPA
receptors (uPAR). Thrombin (Th) in complex
with thrombomodulin (Tm) activates TAFI
(TAFIa), which eliminates plasminogen binding
sites in fibrin. Activated factor XIII (FXIIIa)
confers fibrinolytic resistance through modifi-
cation of fibrin structure and crosslinking of
AP to fibrin.
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Bleeding tendencies based on abnormal
fibrinolysis
Clinical bleeding in the absence of overt mechanical injury is
always the outcome of impaired haemostatic balance stem-
ming either from inadequate pro-coagulant mechanisms or
enhanced fibrinolysis. In certain cases, such as the lack of a
specific inhibitor, the causative relationship between the fib-
rinolytic abnormality and the laboratory findings or clinical
symptoms of the bleeding patient is straightforward. In other
circumstances, defective clotting and abnormal fibrin may
lead to enhanced fibrinolysis but there is no routinely used
standardized laboratory assay (or a panel of assays) that can
clearly identify this relative hyperfibrinolysis. In order to
emphasize the variable role of fibrinolysis in clinical bleeding,
in the following discussion we make a distinction between
primary hyperfibrinolysis (absolute quantitative or qualitative
abnormalities of proteins directly involved in the lytic
process) and secondary hyperfibrinolysis (conditions of imbal-
anced excessive activation of structurally normal fibrinolytic
enzymes or enhanced susceptibility of fibrin to proteolysis).
Both types of haemorrhagic trends can be traced back to
inherited or acquired disease states. The distinction of pri-
mary and secondary hyperfibrinolysis introduced in this
review, and summarized in Table I, is helpful from therapeu-
tic point of view, because it emphasizes what should be the
primary target of treatment (the fibrinolytic system or the
underlying disease state). In addition to the hyperfibrinolytic
states discussed in detail below, Table I presents several less
prevalent conditions with a selected key reference for each
one.
Inherited primary hyperfibrinolysis
Based on their role in the control of protease activity, a
haemorrhagic phenotype can be predicted in cases of failure
Table I. Haemorrhagic conditions related to hyperfibrinolysis.
Class Disease/condition Mechanistic features Effect of antifibrinolytics Reference
Inherited primary
hyperfibrinolysis
a2-PI deficiency Uncontrolled excessive
plasmin activity
Major therapeutic modality See text
PAI-1 deficiency Uncontrolled excessive
plasminogen activation
Major therapeutic modality See text
Quebec platelet disorder Overexpression of uPA in
platelets and excessive
plasminogen activation
Major therapeutic modality Blavignac
et al (2011)
Acquired primary
hyperfibrinolysis
End-stage liver cirrhosis Reduced levels of a2-PI and
TAFI, impaired hepatic
clearance of tPA
Therapeutic benefit, if hyperfibrinolysis
is supported by laboratory findings
See text
Acute promyelocytic
leukaemia
Overexpression of the
tPA-cofactor (S100A10)2-
(annexin A2)2
Beneficial as adjuvant to the basal
ATRA therapy with potential
thrombotic side-effects
See text
Inherited secondary
hyperfibrinolysis
Haemophilia Enhanced lytic susceptibility
of fibrin structure,
impaired TAFI activation
Systemic and local administration
as adjuvant to substitution therapy
See text
FXIII deficiency Enhanced lytic susceptibility
of fibrin structure, impaired
a2-PI crosslinking to fibrin
Isolated case reports for beneficial
effects as adjuvant to substitution
therapy
See text
Dysfibinogenaemias Abnormal fibrin structure,
more susceptible to lysis
Beneficial in cases of mild
bleeding and menorrhagia
Casini et al (2015)
Acquired secondary
hyperfibrinolysis
Trauma DIC Beneficial within 3 h after the injury See text
Thrombolytic therapy Iatrogenic side effect Beneficial effect of acute infusion de Bono and
More (1993)
Cardiopulmonary bypass Excessive plasmin generation
secondary to activation of
coagulation
Beneficial administration according to
specific perioperative protocols
Edmunds (2010)
Systemic amyloidosis DIC Beneficial effect in isolated case reports Colucci
et al (2009)
Malignant prostatic and
other solid tumours
DIC Beneficial effect in isolated case reports Hyman
et al (2011)
Placenta disorders
(placenta accreta)
Release of plasminogen activators
from the uterine and placenta
Efficient control of hyperfibrinolysis Schroder
et al (2015)
a2-PI, a2 plasmin inhibitor; DIC, disseminated intravascular coagulation; FXIII, factor XIII; PAI-1, plasminogen activator inhibitor type 1; TAFI,
thrombin activatable fibrinolysis inhibitor; tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator.
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of the physiological inhibitors of plasmin and plasminogen
activators. Congenital deficiencies of a2-PI and PAI-1 have
been reported in a few patients [e.g. (Maino et al, 2008;
Mehta & Shapiro, 2008)], but the lack of routine laboratory
screening means the real prevalence of these inherited bleed-
ing conditions is unknown.
Depending on the nature of the mutation, the molecular
defect in the structure of a2-PI can result in either lower
plasma concentrations or decreased inhibiting potential
despite normal a2-PI antigen levels in blood. For example,
the mutant a2-PI characterized by Miura and Aoki (1990) is
elongated, with 166 amino acids and consequent misfolding
of the protein; only a minor fraction of the mutant a2-PI is
secreted in the blood (Miura & Aoki, 1990). An a2-PI variant
from a Dutch family (a2-antiplasmin Enschede) was found
to be associated with bleeding in homozygous individuals.
An alanine insertion near the reactive centre converts the
protein from an inhibitor to a substrate of plasmin (Rijken
et al, 1988). Thus, a2-PI antigen determination in plasma
shows normal values, but activity measurements indicate lack
of inhibitor. In young patients with homozygous a2-PI defi-
ciency, haematomas may develop rapidly after minor injuries
and persist for days, and apparently unprovoked intracranial
and joint bleedings occur (Kluft et al, 1982). The phenotype
of heterozygous a2-PI deficiency is expressed as a bleeding
tendency with variable severity following surgery, trauma,
venepuncture or tooth extraction (Kluft et al, 1982). How-
ever, many heterozygous subjects have no such bleeds (Aoki
et al, 1979).
PAI-1 deficiency has also been observed and complete loss
of inhibitory activity in homozygous individuals has been
classified as a moderate bleeding disorder (Fay et al, 1997).
Bleeding has been observed in response to trauma or surgery
but was successfully treated using antifibrinolytic lysine ana-
logues. A single PAI-1 mutation has been well-characterized
in a family including 7 homozygous and 19 heterozygous
members. In this example, a dinucleotide insertion in exon 4
of the gene encoding PAI-1 (SERPINE1) causes a frameshift
and a premature stop codon (Fay et al, 1992) and the shorter
mutant molecule is degraded prior to secretion.
Acquired primary hyperfibrinolysis
More than 100 years ago Goodpasture presented elegant evi-
dence that the haemorrhagic trend in end-stage chronic alco-
holic liver disease develops against the background of
relatively normal blood coagulation capacity (normal blood
and plasma clotting) (Goodpasture, 1914). However, liver
disease patients may develop bleeding or venous thrombotic
complications (e.g. reviewed in Roberts et al, 2010), as many
clotting factors, plasminogen and inhibitors are synthesized
in the liver, leading to a complex coagulopathy. So, while
reduced levels of circulating plasminogen are antifibrinolytic,
reduced levels of a2-PI and TAFI will be profibrinolytic, as
will impaired hepatic clearance of tPA. Thus, it has been
argued there is a rebalancing of the haemostatic system,
which may be driven towards a hypercoagulable state or
hyperfibrinolysis, and the balance may be precarious (Lis-
man, 2012). In practice hyperfibrinolysis was correlated with
the degree of cirrhosis in some studies (Colucci et al, 2003;
Rijken et al, 2012), but not all (Lisman et al, 2001). Rijken
et al (2012) found that the majority of cirrhosis patients
(60%) showed accelerated clot lysis after paying particular
attention to assay methodology using undiluted whole blood
and avoiding the need to add tPA. uPA may also be affected
and contribute to increased fibrinolysis (Booth et al, 1984).
Standardized laboratory testing and large scale prospective
studies are needed to substantiate the administration of
antifibrinolytics to combat hyperfibrinolysis in liver disease
(Gunawan & Runyon, 2006).
Acute promyelocytic leukaemia
Acute promyelocytic leukaemia (APL) is characterized by a
high rate of life-threatening haemorrhagic events related to
hyperfibrinolysis. Despite the normal plasma levels of TAFI
antigen, low TAFI activity has been reported in APL patients
probably due to excessive inactivation of TAFI by plasmin
(Meijers et al, 2000). The primary cause of the bleeding com-
plications appears to be a unique pathway of enhanced plas-
minogen activation. A single genetic defect has been
identified in APL, a translocation between chromosomes 15
and 17 resulting in fusion of the retinoic acid receptor-a
(RAR-a) gene (RARA) and the promyelocytic leukaemia pro-
tein gene (PML). The expressed PML-RAR-a fusion protein
arrests the differentiation of the myeloid precursor cells and
prolongs their survival with consequent APL (Grignani et al,
1993). At the same time, the PML-RAR-a enhances the
expression of S100A10 (p11), a member of the S100 family
of calcium-binding proteins (O’Connell et al, 2011).
S100A10 forms a heterotetrameric (S100A10)2-(annexin A2)2
complex on the surface of various cells, which through its C-
terminal lysine binds plasminogen, tPA and plasmin
(MacLeod et al, 2003). In this way, the (S100A10)2-(annexin
A2)2 complex provides a template for plasminogen activation
on the cell surface and protects plasmin against plasma inhi-
bitors in a similar way to fibrin. These S100A10-related pro-
fibrinolytic effects are consistent with the bleeding profile in
APL. It is noteworthy that annexin A2 is also induced by
PML-RAR-a (Liu et al, 2011) and following proteolytic
cleavage (but not in native form) it binds plasminogen and
tPA (Das et al, 2007). However, because such a cleaved form
has not been demonstrated in vivo, annexin A2 appears to be
important as a complex-forming subunit in the heterote-
trameric template rather than a direct cofactor in plasmino-
gen activation. An established therapeutic modality in APL is
all-trans retinoic acid (ATRA), which induces differentiation
of the leukaemic promyelocytes concomitant with improve-
ment of the haemorrhagic symptoms (Dombret et al, 1993).
ATRA treatment reverses the S100A10 and annexin A2
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induction in PML-RAR-a positive cells and suppresses plas-
min generation on their surface (O’Connell et al, 2011). Ben-
eficial therapeutic effects can be expected from adjuvant
antifibrinolytic treatment in cases with definite laboratory
signs of hyperfibrinolysis, as evidenced by the effect of AHA
in APL patients with a more than 50% reduction in the
plasma a2-PI level, which is used as a marker of excessive
plasmin generation (Wassenaar et al, 2008). An additional
factor for the pro-fibrinolytic state in APL could be the
release of neutrophil elastase from the leukaemic promyelo-
cytes (Oudijk et al, 2000). Despite its lower catalytic effi-
ciency in the degradation of fibrin compared to plasmin,
elastase can promote fibrinolysis, because it converts plas-
minogen to miniplasminogen, a zymogen that is more read-
ily activated, and which inactivates a2-PI (Machovich &
Owen, 1990). Taken together, the evidence justifies the classi-
fication of the haemostatic imbalance in APL as primary
hyperfibrinolysis, and this conclusion is supported by the
typical laboratory findings in the blood of APL patients (nor-
mal prothrombin and activated partial thromboplastin time,
normal antithrombin level, low fibrinogen concentration in
combination with elevated fibrin and fibrinogen degradation
products) (Oudijk et al, 2000).
Inherited secondary hyperfibrinolysis
The term secondary hyperfibrinolysis can be applied for
pathological situations when the members of the fibrinolytic
system have normal structure and availability, but they either
act on fibrin that is more susceptible to lysis or their hyper-
function is provoked in response to overt abnormal systemic
blood clotting. Both inherited and acquired conditions can
result in such alterations of fibrinolytic activity.
Haemophilia
Haemophilia A, B and C are rare congenital deficiencies of
coagulation factors VIII, IX and XI, respectively, that are
accompanied by devastating bleeding episodes, often unpro-
voked in severe cases. Because the culprit factors participate in
the positive feedback circuit of the blood coagulation cascade
mediated by the intrinsic tenase (FVIIIa as cofactor, FIXa as an
executioner protease, FXIa as an activator), their deficiency
causes a striking delay in thrombin generation in the propaga-
tion phase of whole blood clotting, but not at its initiation
(Cawthern et al, 1998). Thus, significant fibrin is formed at
clot time of whole haemophilic blood, suggesting that bleeding
is due to clot instability rather than ab ovo fibrin deficiency.
This concept is supported also by the elevated D-dimer
concentration in the circulation of haemophilic patients
(Grunewald et al, 2002). In view of the effects of thrombin
concentration on fibrin structure, mentioned in the Introduc-
tion, it is not surprising that fibrin architecture is altered
in haemophilic plasma clots. Fibrin formed in haemophilic
plasmas shows thicker fibres, larger pores, lower density
and increased permeability compared to normal plasma
[e.g. (Antovic et al, 2014; Wolberg et al, 2005; Zucker et al,
2014)]. These structural characteristics of the haemophilic
clots augment their susceptibility to tPA-mediated lysis
through improved permeation of the activator, higher potency
of the fibrin structure as a template for plasminogen activation
and more efficient pattern of plasmin digestion. The low-grade
thrombin generation in haemophilia results in a delay in the
activation of TAFI, thereby contributing to the instability of
the haemophilic clots owing to the downregulation of an
essential negative feedback mechanism (Broze & Higuchi,
1996). Supplementation of haemophilic plasma with TAFI
(Mosnier et al, 2001) or soluble thrombomodulin (to stimu-
late TAFIa formation by thrombin-thrombomodulin com-
plex) (Foley & Nesheim, 2009), corrects this defect through
enhancement of TAFI activation and consequent suppression
of fibrinolysis. However, the lack of elevation in the circulating
plasmin-a2-PI complexes in the plasma of bleeding haemophi-
lic patients (Grunewald et al, 2002) suggests that in vivo the
altered fibrin structure is a more important causative factor
for overactive fibrinolysis in haemophilia than the enhance-
ment of plasminogen activation. Furthermore, the reduced
rate of thrombin generation in haemophilia delays the activa-
tion of plasma FXIII (Brummel-Ziedins et al, 2009), which is
an independent factor for clot instability, as discussed in more
detail below. Although the exact mechanistic contribution of
hyperfibrinolysis to the haemorrhagic phenotype of haemo-
philia was essentially unknown, its causative role was
appreciated long ago as reflected in the positive therapeutic
experience with systemic and local administration of
antifibrinolytics (TXA, AHA) for prevention of bleeding in
haemophiliacs at risk (Forbes et al, 1972).
FXIII deficiency
A different type of abnormal fibrin structure originates from
FXIII deficiency, where both inherited and acquired defi-
ciency states occur with low prevalence. The earliest clinical
manifestation of congenital FXIII deficiency is delayed umbil-
ical bleeding, and recurrent subcutaneous and intramuscular
haematomas occur later. Life-threatening intracranial bleed-
ing is often provoked by minor traumas (Anwar & Milos-
zewski, 1999). Most cases of inherited FXIII deficiency are
caused by defects in the gene encoding the catalytic A sub-
unit and a broad array of mutations have been described
(missense and nonsense mutations, splice site defects, inser-
tions and deletions). Only a small number of cases of con-
genital B subunit defects with mild bleeding symptoms have
been described, the loss of the carrier B subunit resulting in
low plasma FXIII levels (whilst platelet FXIII is preserved).
The most common causes of acquired FXIII deficiency are
consumptive depletion (e.g. following major surgery) and
auto-antibodies in systemic lupus erythematosus that block
the activation, the catalytic activity or the fibrin-binding of
subunit A (Souri et al, 2015); or bind to structural domains
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of subunit B with consequent loss of stable plasma FXIII
(Ajzner et al, 2009). Susceptibility of tPA-catalysed fibrin
lysis may be explained by reduced cross-linking and altered
clot structure in the absence of FXIII (Hethershaw et al,
2014). However, in a plasma environment under flow, the
major determinant of the lytic resistance conferred by FXIII
appears to be the crosslinking of a2-PI to fibrin (Fraser et al,
2011). The plasma and whole blood thromboelastograms of
10 patients with congenital FXIII A subunit deficiency evi-
denced accelerated lysis that could be corrected with recom-
binant FXIII replacement therapy (Lovejoy et al, 2006).
Despite convincing evidence for the role of hyperfibrinolysis
in the pathogenesis of bleeding, only isolated case reports
show the potential benefits of antifibrinolytics, for example
oral TXA in acquired FXIII deficiency (Janning et al, 2013).
Acquired secondary hyperfibrinolysis
Disseminated intravascular coagulation (DIC)
In contrast to the rare acquired FXIII deficiency, DIC is a
common severe complication of systemic infection (sepsis)
and extensive tissue destruction (major trauma). DIC is
defined as ‘an acquired syndrome characterized by the
intravascular activation of coagulation with loss of localization
arising from different causes. It can originate from and cause
damage to the microvasculature, which if sufficiently severe,
can produce organ dysfunction’ (Taylor et al, 2001). Innate
immune mechanisms are activated by pathogen-associated
molecular patterns (PAMPs) in sepsis or altered self-tissue
damage-associated molecular patterns (DAMPs) [reviewed by
(Manson et al, 2012)] that provoke pro-thrombotic mecha-
nisms in the microvasculature of the injured tissue to restrict
the propagation of the damaging agent. Recruited monocytes
express tissue factor, which initiates the extrinsic pathway of
blood coagulation, whereas neutrophils release neutrophil
extracellular traps (NETs). Histones, the most abundant pro-
teins in NETs, induce activation of platelets (Fuchs et al,
2011) and endothelial cells (Saffarzadeh et al, 2012) and
inhibit the activated protein C-mediated negative feedback of
the coagulation cascade (Ammollo et al, 2011). If the impaired
anticoagulant pathways cannot localize the pro-thrombotic
factors to the primary injury site, overt multi-organ
microthrombosis develops that is accompanied by activation
of fibrinolysis. The outcome of simultaneous systemic activa-
tion of coagulation and fibrinolysis is consumptive coagulopa-
thy, the laboratory signs of which provide the diagnostic
criteria: thrombocytopenia, prolonged prothrombin time, low
fibrinogen and high circulating levels of fibrin degradation
products (FDP) (Taylor et al, 2001). Depending on the nature
of the provoking factor and the stage of the disease, the phe-
notype of DIC can be either thrombotic or haemorrhagic.
Strong evidence supports the primary role of hyperfibrinolysis
in the early stage of trauma-associated DIC presenting typi-
cally as bleeding and requirement for massive transfusion.
Excessively elevated levels of D-dimers in patients with major
trauma are documented at their hospital admission (Brohi
et al, 2008; Sawamura et al, 2009) and thromboelastography
has confirmed a hyperfibrinolytic state (Kashuk et al, 2010) or
identified enhanced fibrinolysis even in cases when FDP levels
are normal (Perouansky et al, 1999). The pattern of fibri-
nolytic and anticoagulant markers in trauma patients (elevated
D-dimer, tPA and soluble thrombomodulin, low protein C
and normal PAI-1 levels) (Brohi et al, 2008) is consistent with
a pathomechanism initiated by hypoperfusion-induced
endothelial damage in posttraumatic shock. Hypoxia is known
to induce tPA release from endothelial cells, whereas thrombo-
modulin detached from the damaged endothelium promotes
the activation of protein C, which neutralizes PAI-1 (Sakata
et al, 1986). The imbalance of tPA and its inhibitor results in
early hyperfibrinolysis in patients with major traumatic injury,
as discussed in more detail below.
Iatrogenic hyperfibrinolysis: thrombolytic
therapy and bleeding
Thrombolytic therapy for the removal of coronary thrombi
began with first generation plasminogen activators, streptoki-
nase and uPA. First generation thrombolytics were character-
ized by systemic plasminogen activation and bleeding side
effects, in particular serious or fatal cerebral haemorrhage
was a problem (Verstraete, 2000). Uncontrolled plasmin gen-
eration is known to cause depletion of important haemo-
static proteins, including fibrinogen, FV, FVIII and a2-PI,
promoting bleeding (Rick & Krizek, 1986; Lee & Mann,
1989; Nogami et al, 2007). Subsequent development of more
advanced, 2nd and 3rd generation thrombolytics (e.g. Alte-
plase, Reteplase and Tenecteplase,) was spurred on by the
notion that improved fibrin specificity would localize plas-
min activity and reduce bleeding side effects. Unfortunately
the holy grail of finding a therapeutic agent able to leave
existing stable haemostatic plugs intact while targeting new
unwanted thrombus has remained elusive, and significant
intracranial haemorrhage is observed in around 1% of
patients over a range of treatment regimens (Marder & Ste-
wart, 2002). Indeed, the debate on risk/benefit carries on
over treatment for stroke using tPA (Alteplase), currently the
only licensed therapy in the US and Europe. Despite Alte-
plase being licensed since the mid 1980s there are still peri-
odic reviews, though the conclusions and ongoing work still
favour treatment for stroke within 45 h in most countries
(Medicines and Healthcare products Regulatory Agency
2015). The newer thrombolytic drugs have failed to impact
on bleeding risk associated with thrombolytic therapy and
significant future developments are doubtful.
Antifibrinolytics
The goal of antifibrinolytics is to reduce plasmin activity,
which may be achieved at the level of plasminogen
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activation or direct inhibition of plasmin. Both mechanisms
are illustrated by the action of the most well known thera-
peutic antifibrinolytics, aprotinin and the lysine analogues
TXA and AHA. Early evidence of the effectiveness of apro-
tinin (Trasylol) in reducing blood loss and the require-
ment for replacement units was presented (Royston et al,
1987), with some speculation on its mechanism of action.
Plasmin inhibition was the main focus, but possibly acting
by sparing platelet loss and/or preserving von Willebrand
factor-platelet interactions. Aprotinin was used successfully
in cardiopulmonary bypass surgery and other types of vas-
cular, thoracic and orthopaedic surgery (e.g. reviewed by
Henry et al, 2011). However, by 2008, safety concerns sug-
gesting increased risk of renal failure, myocardial infarction
and stroke led to the revocation of licences in Europe and
the US, though the validity of the analysis behind these
decisions is still debated (McMullan & Alston, 2013). Infu-
sion of aprotinin was designed to achieve a circulating con-
centration of 3-4 lM inhibitor, whereas the inhibition
constant (Ki) for aprotinin as an active site inhibitor of
plasmin is 04 nmol/l or 2 nmol/l in the presence of fibrin
(Longstaff, 1994). This apparent discrepancy between Ki
and therapeutic level resulted in proposals for other pro-
tease targets, such as kallikrein. However, plasmin remains
the most likely target and high concentrations of aprotinin
are needed to deal with potentially high concentrations of
plasmin (the circulating concentration of plasminogen is
around 2 lmol/l).
Lysine analogues
Lysine analogues TXA and AHA have been known for many
years as inhibitors of fibrinolysis (reviewed by Roberts,
2015). TXA may be viewed as a more chemically rigid ver-
sion of AHA, fixed by a ring structure into a less flexible,
more active, conformation, with high kringle-binding affin-
ity. Lysine analogues bind to kringle domains to block fibrin
interactions and, as a general rule, TXA demonstrates around
6- to 10-fold higher affinity for lysine binding sites than
AHA (McCormack, 2012). TXA is the more widely used
therapeutic antifibrinolytic, but both lysine analogues and
aprotinin are all effective at reducing blood loss in surgery,
to a similar extent (Henry et al, 2011). It is important to
remember that aprotinin and lysine analogues used in elec-
tive surgery are administered before any blood loss begins, a
more controlled situation than dealing with trauma patients.
Trauma-induced coagulopathy involves diverse pathways:
coagulation factor consumption, DIC, activated protein C
and FXIa, as well haemodilution, hypothermia and acidosis
(Mann & Freeman, 2015). Some patients demonstrate a syn-
drome of hyperfibrinolysis, identified and characterized by
reduced inhibitors, a2-PI, TAFI, PAI-1, and FXIII, in addi-
tion to increased tPA, uPA and elastase (Mann & Freeman,
2015). Hyperfibrinolysis can be detected in some cases by
thromboelastography, and is observed to be a bad prognostic
indicator on admission to the emergency department (Brohi
et al, 2008). However, ROTEM and TEG are relatively insen-
sitive techniques and ongoing fibrinolysis may be better
assessed by measuring raised plasmin-a2-PI complexes or D-
dimer (Raza et al, 2013). The CRASH-2 trial (Shakur et al,
2010) (20 211 patients from 270 hospitals in 40 countries)
demonstrated the successful application of TXA when given
to trauma patients within 8 h. Importantly, there were no
indications of increased risk of vascular occlusion in the trea-
ted group, including myocardial infarction, stroke or pul-
monary embolism. This is important as it has been shown
that failure to prevent severe traumatic bleeding is associated
with increased vascular occlusive events (Pealing et al, 2012).
A subsequent detailed reanalysis of the original CRASH-2
trial data (Roberts et al, 2011) revealed TXA was only effec-
tive at preventing death due to bleeding when given quickly.
In the group treated <3 h the relative risk of death from
bleeding was 068 (95% confidence interval 057–082) while
after 3 h it was 144 (112–184). With this in mind, and
noting the excellent safety profile of TXA (no increased risk
of thrombosis) it has been forcefully argued that any delay in
giving TXA while waiting for test results to confirm ongoing
fibrinolysis (by thromboelastography for example) will result
in thousands of unnecessary deaths (Shakur et al, 2012).
European guidelines to maximize the benefit of TXA recom-
mend aggressive treatment for patients who are bleeding or
at risk of bleeding, with the initial infusion over 10 min,
immediately, on first encounter with the patient (Spahn et al,
2013). Nevertheless, the mechanism underlying the 3 h time
window and the missing detail on exactly how TXA and
plasmin are associated with increasing risk of death in
trauma may leave some room for doubt and hesitation in
the universal uptake of TXA as an immediate first line treat-
ment.
Lysine analogues: mechanism of action
It is worth exploring the possible mechanisms of action of
TXA and probe what basic research might tell us to explain
under what circumstances TXA could be profibrinolytic and
hence ineffective (or dangerous) >3 h after trauma. The cir-
culating concentration of TXA used in surgery and the tar-
get when treating trauma is around 200 lmol/l (Fiechtner
et al, 2001), easily within the range to prevent tPA activa-
tion of plasminogen on fibrin [with an 50% inhibitory con-
centration of <50 lmol/l (Silva et al, 2012), Fig 3A],
suggesting the most likely antifibrinolytic mechanism. A
much higher TXA concentration would be needed to block
the plasmin active site, Ki = 16 mmol/l (Christensen, 1978).
However, TXA can also be profibrinolytic. Above
100 lmol/l, TXA can bind to a plasminogen low affinity
kringle and induce an open conformation that is more acti-
vatable by uPA (but not tPA), with or without fibrin pre-
sent (Sinniger et al, 1999; Silva et al, 2012), as shown in
Fig 3A. Furthermore, once plasmin is generated, inhibition
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by a2-PI is normally rapid in the absence of fibrin (Thel-
well & Longstaff, 2007), but plasmin is protected by TXA
in the range 10–500 lmol/l (Longstaff & Gaffney, 1991).
Another profibrinolytic mechanism has been ascribed to
improved diffusion of plasmin through fibrin clots due to
reduced binding to C-terminal lysines. Thus, fibrinolysis
was enhanced when plasmin was added to fibrin treated
with carboxypepetidase (which removes C-terminal lysines)
(Kovacs et al, 2014) or in the presence of AHA (Varju
et al, 2014), as shown in Fig 3B. The concentration of AHA
used in (Varju et al, 2014) was 1 mmol/l, so applying the
6- to 10-fold rule (McCormack, 2012), a therapeutic
concentration of 100–150 lmol/l TXA may have the same
pro-fibrinolytic effect. Hence, profibrinolytic effects of TXA
are possible under circumstances where uPA develops a sig-
nificant role as activator; or when sufficient free plasmin
has been generated and TXA protects plasmin from inhibi-
tion by a2-PI; or where TXA enhances plasmin diffusion
and degradation of fibrin. Further work is needed to
explore if these hypotheses account for the failure of TXA
to prevent bleeding when given >3 h after trauma. How-
ever, recent work using a mouse model to study delayed
intracranial haemorrhage after traumatic brain injury sup-
ports a major role for enhanced fibrinolysis, and the evolu-
tion of uPA activity in particular (Hijazi et al, 2015). It was
shown that after injury, a spike of tPA appears in the cere-
brospinal fluid, which then rapidly declines, while uPA
release is slower but predominates after 3–4 h. Significantly,
using knockout mice, these authors also demonstrated the
ability of TXA to further stimulate fibrinolysis when uPA is
the plasminogen activator in the absence of tPA, in this
model.
Conclusions and directions for future work
High throughput or rapid screening for disturbances of fibri-
nolysis is difficult and currently available approaches are
poorly standardized. This may explain in part the scarcity of
data associating defects in fibrinolysis with disease states,
compared with the situation for coagulation. However, gen-
ome studies, results with knockout mice, and low numbers
of affected individuals, all suggest the fibrinolysis system is
robust with inbuilt redundancy. A number of inherited
bleeding conditions and some acquired diseases are clearly
linked to hyperfibrinolysis and may be treated with antifibri-
nolytics, and there is a history of successful application of
the lysine analogues AHA and TXA. These simple drugs have
proved useful in reducing blood loss across a range of situa-
tions, including some inherited and acquired haemostasis
disorders, surgery and trauma. Further work directed
towards a complete understanding of the mechanism of
action of antifibrinolytics in different circumstances, or
understanding why they sometimes fail, may extend their safe
use more widely. An important additional line of future
work is the development of standardized diagnostic tests for
identifying the primary role of hyperfibrinolysis in haemor-
rhagic states, which would improve clinical decision making.
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Fig 3. Inhibition or stimulation of fibrinolysis modulated by lysine
binding site interactions. Both figures show fibrin clot lysis data from
purified systems using clots formed by mixing thrombin and fibrino-
gen. Figure 3A shows clear inhibition by tranexamic acid (TXA) of
tissue-type plasminogen activator (tPA) activity in fibrinolysis assays
(open symbols) but stimulation by TXA > 100 lmol/l when uroki-
nase-type plasminogen activator (uPA) is the activator (solid circles)
(from (Silva et al, 2012), with permission). In Fig 3B, clot lysis
achieved by adding plasmin to a preformed fibrin clot is stimulated
by low concentrations of 6-aminohexanoate (AHA) or by car-
boxypeptidase B (CPB) removal of C-terminal lysines in fibrin. Rep-
rinted with permission from: Varju et al (2014). Copyright 2014
American Chemical Society.
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